Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (423)	6/25/1999 7:36:00 PM
From: scaram(o)uche	Respond to of 579

[ yet more parking ] aside....... note that AHP found it compelling to license both the OSIP and SIBI patents....... Thursday May 27, 8:37 am Eastern Time Company Press Release SOURCE: OSI Pharmaceuticals, Inc. OSI Pharmaceuticals Announces Major Expansion of The Anaderm Program With Pfizer UNIONDALE, N.Y., May 27 /PRNewswire/ -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - news) together with its partners Pfizer Inc (NYSE: PFE - news) and New York University, announced today a major expansion of their collaboration in Anaderm Research Corp. The expansion, which will be financed solely by Pfizer, could result in up to $50 million in total payments to OSI over a 6-year period for its R&D activities in the venture. OSI will also receive royalties on sales resulting from successful product development. Founded in 1996, Anaderm is dedicated to the discovery and development of cosmeceuticals, pharmacologically active compounds for use in certain cosmetic and quality-of-life indications, such as skin pigmentation, skin wrinkling, and hair loss. Anaderm applies the modern tools of drug discovery to the development of safe, effective products for these quality-of-life indications. In the expanded program OSI will continue to function as the drug discovery and pre-clinical development arm of Anaderm, providing a full range of capabilities including assay biology, high throughput screening, compound libraries, combinatorial, medicinal, and natural-product chemistry, as well as pharmaceutics, pharmacokinetics and molecular biology. OSI anticipates a significant increase in its staffing of the program to approximately 45 research scientists over the next 18 months. ''We see Pfizer's commitment to the expansion of the Anaderm cosmeceuticals program as testimony to the progress we have made in the initial 3-year period and to the major market opportunity that exists for these quality-of-life products,'' stated Colin Goddard, Ph.D., President and Chief Executive Officer of OSI Pharmaceuticals, Inc. ''The expanded program will allow us to continue our lead-seeking efforts in the program while conducting the pre-clinical development of lead compounds discovered during the first phase of the alliance,'' he added. OSI Pharmaceuticals is a leading drug discovery company with a substantial pipeline of product opportunities for commercialization with the pharmaceutical industry. OSI's research programs are focused in the areas of cancer therapeutics and diagnostics, cosmeceuticals, and anti-infectives. OSI utilizes a comprehensive drug discovery and development capability to facilitate the rapid and cost-effective discovery and development of novel, small molecule compounds in more than 30 research and development programs. OSI is involved in long-term research alliances with Pfizer, Novartis, Hoechst Marion Roussel, Sankyo, and Bayer. Additional information on OSI Pharmaceuticals is available on the World Wide Web at: osip.com This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, uncertainties related to the identification of lead compounds, the successful pre-clinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission. SOURCE: OSI Pharmaceuticals, Inc.

To: scaram(o)uche who wrote (423)	6/25/1999 7:39:00 PM
From: scaram(o)uche	Respond to of 579

[ more, more..... ] Tuesday June 15, 4:36 pm Eastern Time Company Press Release SOURCE: Aurora Biosciences Corporation Aurora Biosciences Enters Into Five Year Technology Acquisition Agreement For Pharmaceutical R&D With Pfizer SAN DIEGO, June 15 /PRNewswire/ -- Aurora Biosciences Corporation (Nasdaq: ABSC - news) announced today that it has entered into an expansive five-year services, systems and technology access agreement for pharmaceutical discovery with Pfizer. Aurora will provide a team of Aurora scientists to pursue new biologies based on targets selected by Pfizer for drug discovery, compound profiling and genomics. The agreement provides Pfizer with access to Aurora's leading-edge and confidential drug discovery technologies which include a broad range of reporters, novel assay constructs, know-how and automated systems. Aurora will manufacture and install its automated master compound storage system, ultra-high throughput screening and multiple ion channel lead discovery platforms and development stations at Pfizer's research facilities worldwide. Pfizer will also receive broad, non-exclusive licenses to Aurora's confidential ultra-fast screening systems, and sensitive fluorescent sensors for detecting activity of cells or proteins. The contracted payments to Aurora under this agreement amount to approximately $50 million during the five-year agreement. This amount could be increased if Pfizer exercises certain options to increase the size of the collaborative research team or acquire additional instruments or sub-systems. Aurora could also receive milestone or profit-share payments related to development or commercialization of compounds identified through use of assays developed in the collaborative research program. Aurora will provide Pfizer with automated screening equipment and assay technology at Pfizer sites in the United States and abroad. ''Our goal is to provide the next generation of discovery services and technologies throughout the pharmaceutical and biotechnology industries. We are delighted that Pfizer, one of the world's leading research based companies, has chosen to acquire Aurora's pharmaceutical discovery technology for use on a world-wide basis across therapeutic areas,'' said Timothy J. Rink, M.D., Sc.D., Aurora's chairman and chief executive officer. ''The addition of Pfizer to our customer base reinforces Aurora's leadership position in supplying advanced service, system and technology solutions for discovery that will drive the pharmaceutical product pipeline in the next millennium,'' said Harry Stylli, Ph.D., M.B.A., Aurora's senior vice president, commercial development. Aurora combines innovative biotechnology with its novel, high-technology automation and software to provide solutions to challenges in drug discovery for the pharmaceutical and biotechnology industries. The Company's core technologies include a broad portfolio of proprietary fluorescence assay technologies; its functional genomics GenomeScreen(TM) program; and systems to miniaturize and automate assays derived from those technologies within a computer-controlled integrated system, capable of searching through expansive libraries of compounds to identify those that might lead to new medicines. Aurora seeks to become a leader in providing services, technology and information that enhance and accelerate its customers' ability to discover new therapeutics through three main strategies: (1) providing customized drug discovery services, allowing the customer to outsource some part or all of its discovery needs, (2) developing and selling systems, instruments and technologies to augment the customer's own discovery efforts, and (3) licensing the Company's growing intellectual property portfolio. Current customers include Bristol-Myers Squibb Co., Eli Lilly and Company, Warner-Lambert, Merck & Co., Inc., Pharmacia & Upjohn, Inc., F. Hoffmann-LaRoche, Inc., Becton-Dickinson, Cytovia, Inc. and Clontech Laboratories, Inc. Statements in this press release that are not strictly historical are ''forward-looking'' statements which involve a high degree of risk and uncertainty. Such forward-looking statements include statements regarding manufacture and delivery of systems under the terms of the agreement. Such statements are only predictions and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include commercial and development risks involved with the Company's new and uncertain technology, risks associated with the dependence on patents and proprietary rights, the ability to attract additional collaborative partners, dependence on existing pharmaceutical and biotechnology collaborations, and the development or availability of competing systems. These factors and others are more fully described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1998 and subsequent Forms 10-Q, as filed with the Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statements. For additional corporate information, visit the Aurora website at aurorabio.com. SOURCE: Aurora Biosciences Corporation

To: scaram(o)uche who wrote (423)	6/25/1999 8:21:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 579

Pfizer has been paying for transcription assays since at least 1996. Yes, it's in the context of a partnership, and royalties will be attached to specific molecules deriving from the work. However, that partnership comes with the condition that a license for any relevant OSIP patents is included in the deal. We're not talking apples and oranges, we're talking apples and apples. Pfizer just didn't access all of the relevant apples. Again, if they can provide justifiable evidence that the patent is invalid, then I'll shut up. Why, under those circumstances, would they be setting up the "Whine Defense" and asking for a jury trial? Let a judge decide it. Why would AHP license the SIBI patent, having licensed the OSIP work, unless the SIBI patent was enabling? BTW, the AHP product is far along in development.... these aren't products that are all years off in the distance. We're talking near-term cash flows. More parking, an excerpt from the OSIP 10-K....... The Company has received communications from Sibia Neuroscience, Inc. ("Sibia") in which Sibia has stated the Company's live-cell assay technology may infringe a patent issued to Sibia covering cell-based 13 <PAGE> 15 assays. The Company does not believe that it is infringing any valid claim of Sibia's patent or of any patents owned by any other third parties. However, there can be no assurance that a contrary position will not be asserted, or that, if asserted, such a position would not prevail. If a patent infringement lawsuit were brought against the Company or its licensees, the Company could incur substantial costs in defense of such a suit, which could have a material adverse effect on the Company's business, financial condition and results of operation, regardless of whether the Company were successful in the defense. Furthermore, if Sibia (or any other third party) were to establish that the Company's assays infringe Sibia's patent (or any patent of any other third party), then the Company would be required to design non-infringing assays or take a license under Sibia's patent. There can be no assurance the Company would successfully design such assays or that such a license would be available on acceptable terms or at all. Moreover, the Company's royalties may be reduced by up to 50% if its licensees or collaborative partners are required to obtain licenses from third parties whose patent rights are infringed by the Company's products, technology or operations.